Swift Well Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 30 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 123.15%
- Ebitda 383.33%
- Net Worth 2.83%
- Total Assets 123.62%
About Swift Well Pharmaceuticals
Swift Well Pharmaceuticals Private Limited (SWPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 January 2020 (Five years 30 days old ). Its registered office is in Bharatpur, Rajasthan, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Asheesh Goyal and Gaurav Goyal serve as directors at the Company.
Company Details
-
Location
Bharatpur, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230RJ2020PTC067815
-
Company No.
067815
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Jan 2020
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Swift Well Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Asheesh Goyal
|
Director | 16-Jan-2020 | Current |
|
Gaurav Goyal
|
Director | 16-Jan-2020 | Current |
Financial Performance of Swift Well Pharmaceuticals.
Swift Well Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 123.15% increase in profit. The company's net worth moved up by a moderate rise of 2.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Swift Well Pharmaceuticals?
Unlock access to Swift Well Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Swift Well Pharmaceuticals?
Unlock and access historical data on people associated with Swift Well Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Swift Well Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Swift Well Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.